These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 665840)

  • 1. Suppression of prolactin by dopamine agonists in schizophrenics and controls.
    Rotrosen J; Angrist B; Clark C; Gershon S; Halpers FS; Sachar EJ
    Am J Psychiatry; 1978 Aug; 135(8):949-51. PubMed ID: 665840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems.
    Davis BM; Davis KL; Mohs RC; Mathé AA; Rothpearl AB; Johns CA; Levy MI; Horvath TB
    Arch Gen Psychiatry; 1985 Mar; 42(3):259-64. PubMed ID: 3977547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal effects of apomorphine in schizophrenia.
    Ferrier IN; Johnstone EC; Crow TJ
    Br J Psychiatry; 1984 Apr; 144():349-57. PubMed ID: 6722395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine receptor alteration in schizophrenia: neuroendocrine evidence.
    Rotrosen J; Angrist BM; Gershon S; Sachar EJ; Halpern FS
    Psychopharmacology (Berl); 1976 Dec; 51(1):1-7. PubMed ID: 827770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms.
    Meltzer HY; Kolakowska T; Fang VS; Fogg L; Robertson A; Lewine R; Strahilevitz M; Busch D
    Arch Gen Psychiatry; 1984 May; 41(5):512-9. PubMed ID: 6721674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
    Scheinin M; Syvälahti EK; Hietala J; Huupponen R; Pihlajamäki K; Seppälä OP; Säkö E
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):441-9. PubMed ID: 2866563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schneider's first-rank symptoms of schizophrenia. An association with increased growth hormone response to apomorphine.
    Whalley LJ; Christie JE; Brown S; Arbuthnott GW
    Arch Gen Psychiatry; 1984 Nov; 41(11):1040-3. PubMed ID: 6497565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of L-DOPA on nigral dopamine neurons and local field potential: comparison with apomorphine and muscimol.
    Xu D; Karain B; Brantley E; Shi WX
    J Pharmacol Exp Ther; 2011 May; 337(2):533-9. PubMed ID: 21330359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
    Fine SA; Frohman LA
    J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
    Meltzer HY; Lee MA; Jayathilake K
    Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
    Hietala J; Koulu M; Scheinin M; Syvälahti E
    Methods Find Exp Clin Pharmacol; 1985 Aug; 7(8):451-4. PubMed ID: 3935892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A neuroendocrine study of supersensitivity in tardive dyskinesia.
    Tamminga CA; Smith RC; Pandey G; Frohman LA; Davis JM
    Arch Gen Psychiatry; 1977 Oct; 34(10):1199-203. PubMed ID: 911219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
    Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
    J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noradrenergic and dopaminergic interrelation in schizophrenia.
    Brambilla F; Marini S; Saito A; Fassone G; Picardi A; Nerozzi D; Pancheri P
    Psychiatry Res; 1994 Sep; 53(3):231-42. PubMed ID: 7870845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine assessment of dopaminergic activity in schizophrenia.
    Rotrosen J; Angrist BM; Gershon S; Sachar EJ; Halpern FS
    Adv Biochem Psychopharmacol; 1977; 16():649-53. PubMed ID: 883563
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuroendocrine studies with dopamine agonists in schizophrenia.
    Rotrosen J; Angrist B; Paquin J
    Psychopharmacol Bull; 1978 Jan; 14(1):14-7. PubMed ID: 625529
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuroendocrine effects of apomorphine: characterization of response patterns and application to schizophrenia research.
    Rotrosen J; Angrist B; Gershon S; Paquin J; Branchey L; Oleshansky M; Halpern F; Sachar EJ
    Br J Psychiatry; 1979 Nov; 135():444-56. PubMed ID: 540209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological difference of L-dopa, apomorphine, and bromocriptine against metoclopramide.
    Fang VS
    Life Sci; 1981 May; 28(19):2143-9. PubMed ID: 7253807
    [No Abstract]   [Full Text] [Related]  

  • 19. Pyridoxine and depression: neuroendocrine aspects.
    Casacchia M; Boni B; Meco G
    Acta Vitaminol Enzymol; 1982; 4(1-2):55-8. PubMed ID: 6812398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of L-dopa and apomorphine on glucagon secretion in man: evidence against central dopaminergic stimulation of glucagon.
    Lorenzi M; Tsalikian E; Bohannon NV; Gerich JE; Karam JH; Forsham PH
    J Clin Endocrinol Metab; 1977 Dec; 45(6):1154-8. PubMed ID: 591612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.